Acute Pulmonary Embolism Therapeutics Market Size in the 7MM is expected to experience positive growth by 2034, estimates DelveInsight

DelveInsight's "Acute Pulmonary Embolism Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Acute Pulmonary Embolism, historical and forecasted epidemiology as well as the Acute Pulmonary Embolism market trends in the United States.

Discover Key Insights into the Acute Pulmonary Embolism Market with DelveInsight's In-Depth Report @ Acute Pulmonary Embolism Market Size - https://www.delveinsight.com/sample-request/acute-pulmonary-embolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acute Pulmonary Embolism Market Report
• In September 2025, 4D Medical received FDA 510(k) clearance for its CT VQ scan, the first non-contrast imaging tool providing quantitative ventilation and perfusion analysis from standard chest CTs. This technology aids in detecting pulmonary embolism, assessing CTEPH and other lung conditions, and supporting surgical planning.
• In September 2025, Imperative Care received FDA 510(k) clearance for its Symphony® Thrombectomy System to treat pulmonary embolism (PE), expanding its previous use in venous thrombosis to address the full spectrum of venous thromboembolism (VTE).
• Based on secondary analysis, the incidence of pulmonary embolism in the US was found to be 115 cases per 100,000 population.
• Approximately 162 per 100,000 people in the US develop Deep Vein Thrombosis (DVT) each year, highlighting a crucial connection most Acute Pulmonary Embolism cases happen when a DVT clot breaks loose and travels to the lungs, transforming a treatable vein clot into a serious, life-threatening condition.
• In Germany, the incidence of Acute Pulmonary Embolism is estimated at 115 cases per 100,000, with a slightly higher rate in men 130 per 100,000 compared to women 110 per 100,000, highlighting a modest gender difference in occurrence.
• In the UK, the incidence of Acute Pulmonary Embolism is estimated at 7-8 cases per 10,000 people, with risk increasing sharply with age approximately 1 in 10,000 among those under 40 and as high as 1 in 100 in individuals over 80, highlighting how advancing age significantly raises susceptibility.
• The total incidence of Acute Pulmonary Embolism in Japan is estimated to be approximately 6.7 cases per 100,000 population.
• The epidemiology of Acute Pulmonary Embolism is expected to change during the forecast period (2025-2034).
• The leading Acute Pulmonary Embolism Companies such as Akura Medical, Angiodynamics Inc. Penumbra Inc., Agen Biomedical, Daiichi Sankyo, Boston Scientific Corporation, Tasly Biopharmaceuticals Co., Ltd., Echosense Ltd, Magneto Thrombectomy Solutions, Eisai Inc., and others.
• Promising Acute Pulmonary Embolism Therapies such as Anticoagulation, DS-9231, Recombinant Human Prourokinase, Alteplase, Tinzaparin, Acenocoumarol, Inhaled Nitric Oxide and others.

Discover which therapies are expected to grab the Acute Pulmonary Embolism Market Share @ Acute Pulmonary Embolism Market Outlook- https://www.delveinsight.com/sample-request/acute-pulmonary-embolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Pulmonary Embolism Epidemiology Insights
The epidemiology section of Acute Pulmonary Embolism offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Acute Pulmonary Embolism Epidemiology trends @ Acute Pulmonary Embolism Prevalence- https://www.delveinsight.com/sample-request/acute-pulmonary-embolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Pulmonary Embolism Marketed Drugs
• SAVAYSA (edoxaban): Daiichi Sankyo
SAVAYSA (edoxaban), developed by Daiichi Sankyo, is an oral, once-daily selective factor Xa inhibitor approved in the US for the treatment of DVT and Acute Pulmonary Embolism following 5-10 days of initial parenteral anticoagulation. It also reduces the risk of stroke and systemic embolism in patients with NVAF who have a creatinine clearance of 95 mL/min or less, offering an alternative to warfarin with a favorable risk profile in this subgroup.

• ELIQUIS (apixaban): Pfizer/ Bristol Myers Squibb
ELIQUIS (apixaban) is an oral Factor Xa inhibitor that blocks clotting at a key step to reduce thrombin generation and clot formation. It is FDA-approved in the US for preventing and treating DVT, Acute Pulmonary Embolism, and stroke in non-valvular atrial fibrillation, with proven safety and efficacy from seven Phase III trials. ELIQUIS comes as 2.5 mg and 5 mg tablets, with standard inactive ingredients and a film coating. Its convenient dosing and lower bleeding risk make it a widely used anticoagulant.

Acute Pulmonary Embolism Treatment Market Landscape
The Acute Pulmonary Embolism treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acute Pulmonary Embolism has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Acute Pulmonary Embolism treatment guidelines, visit @ Acute Pulmonary Embolism Treatment Market Landscape- https://www.delveinsight.com/sample-request/acute-pulmonary-embolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Pulmonary Embolism Market Outlook
The report's outlook on the Acute Pulmonary Embolism market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Pulmonary Embolism therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Pulmonary Embolism drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders.

Acute Pulmonary Embolism Drugs Uptake
The drug chapter of the Acute Pulmonary Embolism report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Pulmonary Embolism.

Major Acute Pulmonary Embolism Companies
Akura Medical, Angiodynamics Inc. Penumbra Inc., Agen Biomedical, Daiichi Sankyo, Boston Scientific Corporation, Tasly Biopharmaceuticals Co., Ltd., Echosense Ltd, Magneto Thrombectomy Solutions, Eisai Inc and others.

Learn more about the FDA-approved drugs for Acute Pulmonary Embolism @ Drugs for Acute Pulmonary Embolism Treatment- https://www.delveinsight.com/sample-request/acute-pulmonary-embolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acute Pulmonary Embolism Market Report
• Coverage- 7MM
• Forecast Period- 2025-2034
• Acute Pulmonary Embolism Companies- Akura Medical, Angiodynamics Inc. Penumbra Inc., Agen Biomedical, Daiichi Sankyo, Boston Scientific Corporation, Tasly Biopharmaceuticals Co., Ltd., Echosense Ltd, Magneto Thrombectomy Solutions, Eisai Inc. and others.
• Acute Pulmonary Embolism Therapies- Anticoagulation, DS-9231, Recombinant Human Prourokinase, Alteplase, Tinzaparin, Acenocoumarol, Inhaled Nitric Oxide and others.
• Acute Pulmonary Embolism Market Dynamics: Acute Pulmonary Embolism Market Drivers and Barriers
• Acute Pulmonary Embolism Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Acute Pulmonary Embolism Drugs in development @ Acute Pulmonary Embolism Clinical Trials Assessment- https://www.delveinsight.com/sample-request/acute-pulmonary-embolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Acute Pulmonary Embolism Market Overview at a Glance
4. Executive Summary of Acute Pulmonary Embolism
5. Key Events
6. Acute Pulmonary Embolism Epidemiology and Market Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Acute Pulmonary Embolism Marketed Therapies
11. Acute Pulmonary Embolism Emerging Therapies
12. Acute Pulmonary Embolism: Market Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.